乳腺癌
雌激素受体
医学
三阴性乳腺癌
肿瘤科
癌症
药物开发
内科学
癌症研究
生物信息学
药品
药理学
生物
作者
Elisa Agostinetto,Giuseppe Curigliano,Martine Piccart
标识
DOI:10.1016/j.xcrm.2024.101575
摘要
Patients with human epidermal receptor 2 (HER2)-positive breast cancer are experiencing a consistent shift toward better survival across the years, thanks to tremendous advancements in treatment strategies. The consistent improvements of outcomes set a high bar for new drug development and the need to explore new ways to overcome resistance mechanisms. Emerging treatments in HER2-positive breast cancer aim to tackle the disease by acting on different targets, including not only HER2 (both at the extra- and intracellular level), but also HER3, PD-(L)1, CTLA4, NKG2A, AKT, PI3K, and, in triple-positive tumors, the estrogen receptors and the cyclin-dependent kinases 4/6. This review describes the evolving treatment landscape of HER2-positive breast cancer, from the current approved therapies to the future perspectives, with a focus on the new agents which are likely to get approved in the next future.
科研通智能强力驱动
Strongly Powered by AbleSci AI